AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the European Commission (EC) to treat chronic lymphocytic leukaemia (CLL) in the ...

SEC Filings Published 06/06/2025, 08:05 AM 0 astrazeneca’s calquence receives eu approval for 1l cll treatment AZN 0.22% AZN ...

Calquence is approved for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the US, Japan and China, and approved for CLL in the EU and many other countries.

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously untreated ...

Calquence is also being evaluated as a potential 1st-line treatment for patients with MCL, in combination with bendamustine and rituximab in the Phase 3 ACE-LY-308 clinical trial, which has an ...

AstraZeneca noted that the approval of Calquence, in combination with venetoclax, follows the positive opinion of the Committee for Medicinal Products for Human Use and was based on positive ...

Calquence is also in trials for a range of B-cell malignancies and other cancers including chronic lymphocytic leukaemia (CLL), MCL, Waldenström macroglobulinaemia (WM), follicular lymphoma ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...